Results from Phase 3 clinical trial, OAK, assessing Roche�s $ROG TECENTRIQ (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) showed an encouraging treatment effect over chemotherapy. The data was showed at the European Society of Medical Oncology 2016 Annual Meeting in Copenhagen. The trial demonstrated NSCLC patients treated TECENTRIQ lived a median of 4.2 months longer than those treated with docetaxel (13.8 months versus 9.6 months) irrespective of their level of PD-1 expression. NSCLC is a Breakthrough Therapy Indication. The drug-maker�s supplemental Biologics License Application (sBLA) is currently under the FDA�s priority review with an action data of October 19.